What is Leerink Partnrs' Forecast for CRBU FY2025 Earnings?

Key Points

• Leerink Partners raised their FY2025 earnings estimate for Caribou Biosciences to ($1.57) per share from a previous estimate of ($1.64).
• Shares of Caribou Biosciences increased by 1.3%, trading at $2.03 with a notable market cap of $188.66 million.
• Caribou's latest earnings report showed a loss of ($0.35) EPS for the quarter, which was better than the consensus estimate of ($0.40).

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2025 EPS estimates for Caribou Biosciences in a research report issued on Tuesday, August 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.57) for the year, up from their previous forecast of ($1.64). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.73) EPS, FY2027 earnings at ($1.82) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($0.81) EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $2.67 million during the quarter, compared to analysts' expectations of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%.

A number of other brokerages have also recently weighed in on CRBU. HC Wainwright restated a "buy" rating and set a $3.00 target price (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. Wall Street Zen cut shares of Caribou Biosciences from a "hold" rating to a "sell" rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Up 1.7%

NASDAQ:CRBU traded up $0.03 during trading hours on Friday, reaching $1.80. 471,608 shares of the company's stock were exchanged, compared to its average volume of 1,342,431. The company has a market capitalization of $167.62 million, a P/E ratio of -1.01 and a beta of 2.55. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $2.9995. The business's 50-day simple moving average is $1.69 and its two-hundred day simple moving average is $1.25.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its position in Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after buying an additional 2,062,563 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Caribou Biosciences by 28.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after purchasing an additional 467,738 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Caribou Biosciences by 39.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after purchasing an additional 416,600 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Caribou Biosciences by 19.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock valued at $1,317,000 after purchasing an additional 234,052 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Caribou Biosciences by 23.7% during the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company's stock valued at $1,779,000 after purchasing an additional 214,239 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.